Miraculins develops new assay in preeclampsia program

Miraculins (TSX-V:MOM) has developed an ultrasensitive assay for the detection of soluble endoglin, optimized for serum and urine, in an ELISA format as part of its preeclampsia program.  Endoglin is the lead biomarker in its preeclampsia portfolio. “Our initial focus will be to offer this assay to investigators as a research-use-only kit to support preeclampsia [...]

Miraculins to license PreVu from PreMD

Miraculins (TSX-V:MOM) has signed a letter of intent to license the exclusive worldwide rights of the PreVu skin cholesterol test from PreMD. The non-invasive diagnostic test for skin tissue cholesterol has received FDA clearance and has been successfully test marketed in the U.S. and Canada.  If definitive documentation is not reached, or the exclusivity period [...]

Miraculins amends private placement offering

Miraculins (TSX-V:MOM) has raised the number of units in a previously announced private placement to 10 million from 7.5 million, with the units priced at five cents each instead of seven cents, for gross proceeds of $500,000. Each unit will consist of one common share of the company and one warrant.  Each warrant can be [...]

Miraculins in private placement

Miraculins (TSX-V:MOM) has announced a non-brokered private placement of up to 7.15 million units at a price of seven cents a unit for gross proceeds of up to $500,500. Net proceeds will be used by the medical diagnostics company for the research and development, and for working capital. Each unit consists of one common share [...]